| Identification | Back Directory | [Name]
JNJ 17029259 | [CAS]
314267-57-7 | [Synonyms]
JNJ 17029259
4-[4-(2-aminopropan-2-yl)phenyl]-2-[4-(2-morpholin-4-ylethyl)anilino]pyrimidine-5-carbonitrile
5-Pyrimidinecarbonitrile, 4-[4-(1-amino-1-methylethyl)phenyl]-2-[[4-[2-(4-morpholinyl)ethyl]phenyl]amino]- | [Molecular Formula]
C26H30N6O | [MDL Number]
MFCD25977027 | [MOL File]
314267-57-7.mol | [Molecular Weight]
442.56 |
| Hazard Information | Back Directory | [Uses]
JNJ 17029259 is an orally active and selective VEGF-R2 kinase inhibitor. JNJ 17029259 inhibits VEGF-mediated signal transduction. JNJ 17029259 has anti-angiogenic activity[1][2]. | [References]
[1] Mohammed S. I. Makki, et al. Fluorine Substituted 1,2,4-Triazinones as Potential Anti-HIV-1 and CDK2 Inhibitors. Journal of Chemistry. 2014. Article ID 430573.
[2] Reuman M, et al. Scalable synthesis of the VEGF-R2 kinase inhibitor JNJ-17029259 using ultrasound-mediated addition of MeLi-CeCl3 to a nitrile. J Org Chem. 2008 Feb 1;73(3):1121-3. DOI:10.1021/jo7021372 |
|
|